Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data ReleaseSeeking Alpha • 05/30/25
Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.Barrons • 05/30/25
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile FailureInvestors Business Daily • 05/30/25
Summit Therapeutics' Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival EndpointBenzinga • 05/30/25
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global StudyBusiness Wire • 05/30/25
Does Summit Therapeutics (SMMT) Have the Potential to Rally 44.6% as Wall Street Analysts Expect?Zacks Investment Research • 05/26/25
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should KnowZacks Investment Research • 05/06/25
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025Business Wire • 05/01/25
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged TodayThe Motley Fool • 04/25/25
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in ChinaBusiness Wire • 04/25/25
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025Business Wire • 04/24/25
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in ChinaBusiness Wire • 04/23/25